Comparative Pharmacology
Head-to-head clinical analysis: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus RENOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus RENOTEC.
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs RENOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinapril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Renotec is a direct renin inhibitor that binds to the active site of renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and lowering blood pressure.
Initial: 10/12.5 mg (quinapril/hydrochlorothiazide) orally once daily. Titrate based on response to a maximum of 40/25 mg once daily.
Enalapril 5-40 mg orally once or twice daily; initial dose 5 mg once daily, titrate based on response.
None Documented
None Documented
Quinaprilat terminal half-life ~25 hours (effective half-life ~12 hours); hydrochlorothiazide ~6-15 hours (increased in renal impairment).
Terminal elimination half-life is 12-15 hours; clinical context: supports once-daily dosing; half-life may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal excretion of quinaprilat (active metabolite) ~50-60% unchanged; hydrochlorothiazide ~70% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Approximately 70% of the dose is excreted in urine as unchanged drug, and 20-30% via feces as metabolites; less than 5% is excreted unchanged in feces.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor